Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 31,500 shares, a decline of 58.7% from the December 15th total of 76,200 shares. Based on an average daily volume of 787,700 shares, the short-interest ratio is currently 0.0 days.

Astellas Pharma Stock Performance

ALPMY stock opened at $9.70 on Thursday. The stock’s 50 day simple moving average is $10.14 and its 200 day simple moving average is $11.02. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $13.14. The firm has a market cap of $17.54 billion, a P/E ratio of 46.17 and a beta of 0.34. The company has a current ratio of 0.90, a quick ratio of 0.72 and a debt-to-equity ratio of 0.26.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. The company had revenue of $3.11 billion for the quarter. As a group, equities research analysts predict that Astellas Pharma will post 0.61 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.